The Calcemic Response to Continuous Parathyroid Hormone (PTH)(1-34) Infusion in End-Stage Kidney Disease Varies According to Bone Turnover: A Potential Role for PTH(7-84)
Context: Factors contributing to PTH resistance in dialysis patients remain elusive. Objectives: The study assessed the skeletal and biochemical response to 46 h of PTH(1-34) infusion in dialysis patients. Design: The study was a prospective, controlled assessment of response to PTH(1-34). Setting:...
Saved in:
| Published in | The journal of clinical endocrinology and metabolism Vol. 95; no. 6; pp. 2772 - 2780 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Bethesda, MD
Oxford University Press
01.06.2010
Copyright by The Endocrine Society Endocrine Society The Endocrine Society |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Context: Factors contributing to PTH resistance in dialysis patients remain elusive.
Objectives: The study assessed the skeletal and biochemical response to 46 h of PTH(1-34) infusion in dialysis patients.
Design: The study was a prospective, controlled assessment of response to PTH(1-34).
Setting: The study was performed at the University of California, Los Angeles, General Clinical Research Center.
Participants: Nineteen dialysis patients and 17 healthy volunteers were studied.
Intervention: PTH(1-34) was infused at a rate of 8 pmol/kg · h for 46 h. Bone biopsy was performed in all dialysis patients.
Main Outcome Measures: Serum calcium, phosphorus, 1,25-dihydroxyvitamin D, PTH (four separate assays), and FGF-23 were determined at baseline and h 7, 23, 35, and 46 of the infusion.
Results: Serum calcium levels rose in healthy volunteers (9.2 ± 0.1 to 11.9 ± 0.3 mg/dl; P < 0.01) and in dialysis patients with adynamic/normal bone turnover (9.0 ± 0.3 to 10.7 ± 0.7 mg/dl; P < 0.05) but did not change in dialysis patients with high bone turnover. Serum phosphorus levels declined in healthy volunteers (3.9 ± 0.1 to 3.5 ± 0.1 mg/dl; P < 0.05) but increased in all dialysis patients (6.7 ± 0.4 to 8.0 ± 0.3 mg/dl; P < 0.05). Full-length PTH(1-84) declined in all subjects; however, PTH(7-84) fragments declined only in healthy subjects and in dialysis patients with normal/adynamic bone but remained unchanged in dialysis patients with high bone turnover.
Conclusions: The skeleton of dialysis patients with high bone turnover is resistant to the calcemic actions of PTH. PTH(7-84) may contribute to this phenomenon.The skeleton of dialysis patients with high bone turnover is resistant to the calcemic actions of PTH and PTH(7-84) may contribute to this phenomenon. |
|---|---|
| AbstractList | CONTEXT:Factors contributing to PTH resistance in dialysis patients remain elusive.
OBJECTIVES:The study assessed the skeletal and biochemical response to 46 h of PTH(1-34) infusion in dialysis patients.
DESIGN:The study was a prospective, controlled assessment of response to PTH(1-34).
SETTING:The study was performed at the University of California, Los Angeles, General Clinical Research Center.
PARTICIPANTS:Nineteen dialysis patients and 17 healthy volunteers were studied.
INTERVENTION:PTH(1-34) was infused at a rate of 8 pmol/kg · h for 46 h. Bone biopsy was performed in all dialysis patients.
MAIN OUTCOME MEASURES:Serum calcium, phosphorus, 1,25-dihydroxyvitamin D, PTH (four separate assays), and FGF-23 were determined at baseline and h 7, 23, 35, and 46 of the infusion.
RESULTS:Serum calcium levels rose in healthy volunteers (9.2 ± 0.1 to 11.9 ± 0.3 mg/dl; P < 0.01) and in dialysis patients with adynamic/normal bone turnover (9.0 ± 0.3 to 10.7 ± 0.7 mg/dl; P < 0.05) but did not change in dialysis patients with high bone turnover. Serum phosphorus levels declined in healthy volunteers (3.9 ± 0.1 to 3.5 ± 0.1 mg/dl; P < 0.05) but increased in all dialysis patients (6.7 ± 0.4 to 8.0 ± 0.3 mg/dl; P < 0.05). Full-length PTH(1-84) declined in all subjects; however, PTH(7-84) fragments declined only in healthy subjects and in dialysis patients with normal/adynamic bone but remained unchanged in dialysis patients with high bone turnover.
CONCLUSIONS:The skeleton of dialysis patients with high bone turnover is resistant to the calcemic actions of PTH. PTH(7-84) may contribute to this phenomenon. Context: Factors contributing to PTH resistance in dialysis patients remain elusive. Objectives: The study assessed the skeletal and biochemical response to 46 h of PTH(1-34) infusion in dialysis patients. Design: The study was a prospective, controlled assessment of response to PTH(1-34). Setting: The study was performed at the University of California, Los Angeles, General Clinical Research Center. Participants: Nineteen dialysis patients and 17 healthy volunteers were studied. Intervention: PTH(1-34) was infused at a rate of 8 pmol/kg · h for 46 h. Bone biopsy was performed in all dialysis patients. Main Outcome Measures: Serum calcium, phosphorus, 1,25-dihydroxyvitamin D, PTH (four separate assays), and FGF-23 were determined at baseline and h 7, 23, 35, and 46 of the infusion. Results: Serum calcium levels rose in healthy volunteers (9.2 ± 0.1 to 11.9 ± 0.3 mg/dl; P < 0.01) and in dialysis patients with adynamic/normal bone turnover (9.0 ± 0.3 to 10.7 ± 0.7 mg/dl; P < 0.05) but did not change in dialysis patients with high bone turnover. Serum phosphorus levels declined in healthy volunteers (3.9 ± 0.1 to 3.5 ± 0.1 mg/dl; P < 0.05) but increased in all dialysis patients (6.7 ± 0.4 to 8.0 ± 0.3 mg/dl; P < 0.05). Full-length PTH(1-84) declined in all subjects; however, PTH(7-84) fragments declined only in healthy subjects and in dialysis patients with normal/adynamic bone but remained unchanged in dialysis patients with high bone turnover. Conclusions: The skeleton of dialysis patients with high bone turnover is resistant to the calcemic actions of PTH. PTH(7-84) may contribute to this phenomenon. Context: Factors contributing to PTH resistance in dialysis patients remain elusive. Objectives: The study assessed the skeletal and biochemical response to 46 h of PTH(1-34) infusion in dialysis patients. Design: The study was a prospective, controlled assessment of response to PTH(1-34). Setting: The study was performed at the University of California, Los Angeles, General Clinical Research Center. Participants: Nineteen dialysis patients and 17 healthy volunteers were studied. Intervention: PTH(1-34) was infused at a rate of 8 pmol/kg · h for 46 h. Bone biopsy was performed in all dialysis patients. Main Outcome Measures: Serum calcium, phosphorus, 1,25-dihydroxyvitamin D, PTH (four separate assays), and FGF-23 were determined at baseline and h 7, 23, 35, and 46 of the infusion. Results: Serum calcium levels rose in healthy volunteers (9.2 ± 0.1 to 11.9 ± 0.3 mg/dl; P < 0.01) and in dialysis patients with adynamic/normal bone turnover (9.0 ± 0.3 to 10.7 ± 0.7 mg/dl; P < 0.05) but did not change in dialysis patients with high bone turnover. Serum phosphorus levels declined in healthy volunteers (3.9 ± 0.1 to 3.5 ± 0.1 mg/dl; P < 0.05) but increased in all dialysis patients (6.7 ± 0.4 to 8.0 ± 0.3 mg/dl; P < 0.05). Full-length PTH(1-84) declined in all subjects; however, PTH(7-84) fragments declined only in healthy subjects and in dialysis patients with normal/adynamic bone but remained unchanged in dialysis patients with high bone turnover. Conclusions: The skeleton of dialysis patients with high bone turnover is resistant to the calcemic actions of PTH. PTH(7-84) may contribute to this phenomenon. The skeleton of dialysis patients with high bone turnover is resistant to the calcemic actions of PTH and PTH(7-84) may contribute to this phenomenon. Factors contributing to PTH resistance in dialysis patients remain elusive. The study assessed the skeletal and biochemical response to 46 h of PTH(1-34) infusion in dialysis patients. The study was a prospective, controlled assessment of response to PTH(1-34). The study was performed at the University of California, Los Angeles, General Clinical Research Center. Nineteen dialysis patients and 17 healthy volunteers were studied. PTH(1-34) was infused at a rate of 8 pmol/kg x h for 46 h. Bone biopsy was performed in all dialysis patients. Serum calcium, phosphorus, 1,25-dihydroxyvitamin D, PTH (four separate assays), and FGF-23 were determined at baseline and h 7, 23, 35, and 46 of the infusion. Serum calcium levels rose in healthy volunteers (9.2 +/- 0.1 to 11.9 +/- 0.3 mg/dl; P < 0.01) and in dialysis patients with adynamic/normal bone turnover (9.0 +/- 0.3 to 10.7 +/- 0.7 mg/dl; P < 0.05) but did not change in dialysis patients with high bone turnover. Serum phosphorus levels declined in healthy volunteers (3.9 +/- 0.1 to 3.5 +/- 0.1 mg/dl; P < 0.05) but increased in all dialysis patients (6.7 +/- 0.4 to 8.0 +/- 0.3 mg/dl; P < 0.05). Full-length PTH(1-84) declined in all subjects; however, PTH(7-84) fragments declined only in healthy subjects and in dialysis patients with normal/adynamic bone but remained unchanged in dialysis patients with high bone turnover. The skeleton of dialysis patients with high bone turnover is resistant to the calcemic actions of PTH. PTH(7-84) may contribute to this phenomenon. Factors contributing to PTH resistance in dialysis patients remain elusive.CONTEXTFactors contributing to PTH resistance in dialysis patients remain elusive.The study assessed the skeletal and biochemical response to 46 h of PTH(1-34) infusion in dialysis patients.OBJECTIVESThe study assessed the skeletal and biochemical response to 46 h of PTH(1-34) infusion in dialysis patients.The study was a prospective, controlled assessment of response to PTH(1-34).DESIGNThe study was a prospective, controlled assessment of response to PTH(1-34).The study was performed at the University of California, Los Angeles, General Clinical Research Center.SETTINGThe study was performed at the University of California, Los Angeles, General Clinical Research Center.Nineteen dialysis patients and 17 healthy volunteers were studied.PARTICIPANTSNineteen dialysis patients and 17 healthy volunteers were studied.PTH(1-34) was infused at a rate of 8 pmol/kg x h for 46 h. Bone biopsy was performed in all dialysis patients.INTERVENTIONPTH(1-34) was infused at a rate of 8 pmol/kg x h for 46 h. Bone biopsy was performed in all dialysis patients.Serum calcium, phosphorus, 1,25-dihydroxyvitamin D, PTH (four separate assays), and FGF-23 were determined at baseline and h 7, 23, 35, and 46 of the infusion.MAIN OUTCOME MEASURESSerum calcium, phosphorus, 1,25-dihydroxyvitamin D, PTH (four separate assays), and FGF-23 were determined at baseline and h 7, 23, 35, and 46 of the infusion.Serum calcium levels rose in healthy volunteers (9.2 +/- 0.1 to 11.9 +/- 0.3 mg/dl; P < 0.01) and in dialysis patients with adynamic/normal bone turnover (9.0 +/- 0.3 to 10.7 +/- 0.7 mg/dl; P < 0.05) but did not change in dialysis patients with high bone turnover. Serum phosphorus levels declined in healthy volunteers (3.9 +/- 0.1 to 3.5 +/- 0.1 mg/dl; P < 0.05) but increased in all dialysis patients (6.7 +/- 0.4 to 8.0 +/- 0.3 mg/dl; P < 0.05). Full-length PTH(1-84) declined in all subjects; however, PTH(7-84) fragments declined only in healthy subjects and in dialysis patients with normal/adynamic bone but remained unchanged in dialysis patients with high bone turnover.RESULTSSerum calcium levels rose in healthy volunteers (9.2 +/- 0.1 to 11.9 +/- 0.3 mg/dl; P < 0.01) and in dialysis patients with adynamic/normal bone turnover (9.0 +/- 0.3 to 10.7 +/- 0.7 mg/dl; P < 0.05) but did not change in dialysis patients with high bone turnover. Serum phosphorus levels declined in healthy volunteers (3.9 +/- 0.1 to 3.5 +/- 0.1 mg/dl; P < 0.05) but increased in all dialysis patients (6.7 +/- 0.4 to 8.0 +/- 0.3 mg/dl; P < 0.05). Full-length PTH(1-84) declined in all subjects; however, PTH(7-84) fragments declined only in healthy subjects and in dialysis patients with normal/adynamic bone but remained unchanged in dialysis patients with high bone turnover.The skeleton of dialysis patients with high bone turnover is resistant to the calcemic actions of PTH. PTH(7-84) may contribute to this phenomenon.CONCLUSIONSThe skeleton of dialysis patients with high bone turnover is resistant to the calcemic actions of PTH. PTH(7-84) may contribute to this phenomenon. Context: Factors contributing to PTH resistance in dialysis patients remain elusive. Objectives: The study assessed the skeletal and biochemical response to 46 h of PTH(1-34) infusion in dialysis patients. Design: The study was a prospective, controlled assessment of response to PTH(1-34). Setting: The study was performed at the University of California, Los Angeles, General Clinical Research Center. Participants: Nineteen dialysis patients and 17 healthy volunteers were studied. Intervention: PTH(1-34) was infused at a rate of 8 pmol/kg · h for 46 h. Bone biopsy was performed in all dialysis patients. Main Outcome Measures: Serum calcium, phosphorus, 1,25-dihydroxyvitamin D, PTH (four separate assays), and FGF-23 were determined at baseline and h 7, 23, 35, and 46 of the infusion. Results: Serum calcium levels rose in healthy volunteers (9.2 ± 0.1 to 11.9 ± 0.3 mg/dl; P < 0.01) and in dialysis patients with adynamic/normal bone turnover (9.0 ± 0.3 to 10.7 ± 0.7 mg/dl; P < 0.05) but did not change in dialysis patients with high bone turnover. Serum phosphorus levels declined in healthy volunteers (3.9 ± 0.1 to 3.5 ± 0.1 mg/dl; P < 0.05) but increased in all dialysis patients (6.7 ± 0.4 to 8.0 ± 0.3 mg/dl; P < 0.05). Full-length PTH(1-84) declined in all subjects; however, PTH(7-84) fragments declined only in healthy subjects and in dialysis patients with normal/adynamic bone but remained unchanged in dialysis patients with high bone turnover. Conclusions: The skeleton of dialysis patients with high bone turnover is resistant to the calcemic actions of PTH. PTH(7-84) may contribute to this phenomenon.The skeleton of dialysis patients with high bone turnover is resistant to the calcemic actions of PTH and PTH(7-84) may contribute to this phenomenon. |
| Author | Harkins, G. Chris Elashoff, Robert Jüppner, Harald Wang, He-jing Salusky, Isidro B. Wesseling-Perry, Katherine Stewart, Andrew F. Gales, Barbara Horwitz, Mara J. |
| AuthorAffiliation | David Geffen School of Medicine at University of California, Los Angeles (K.W.-P., H.W., R.E., B.G., I.B.S.), Los Angeles, California 90095; Immutopics International (G.C.H.), San Clemente, California 92673; The University of Pittsburgh School of Medicine (M.J.H., A.F.S.), Pittsburgh, Pennsylvania 15213; and Massachusetts General Hospital and Harvard Medical School (H.J.), Boston, Massachusetts 02114 |
| AuthorAffiliation_xml | – name: David Geffen School of Medicine at University of California, Los Angeles (K.W.-P., H.W., R.E., B.G., I.B.S.), Los Angeles, California 90095; Immutopics International (G.C.H.), San Clemente, California 92673; The University of Pittsburgh School of Medicine (M.J.H., A.F.S.), Pittsburgh, Pennsylvania 15213; and Massachusetts General Hospital and Harvard Medical School (H.J.), Boston, Massachusetts 02114 |
| Author_xml | – sequence: 1 givenname: Katherine surname: Wesseling-Perry fullname: Wesseling-Perry, Katherine email: kwesseling@mednet.ucla.edu organization: 1David Geffen School of Medicine at University of California, Los Angeles (K.W.-P., H.W., R.E., B.G., I.B.S.), Los Angeles, California 90095 – sequence: 2 givenname: G. Chris surname: Harkins fullname: Harkins, G. Chris organization: 2Immutopics International (G.C.H.), San Clemente, California 92673 – sequence: 3 givenname: He-jing surname: Wang fullname: Wang, He-jing organization: 1David Geffen School of Medicine at University of California, Los Angeles (K.W.-P., H.W., R.E., B.G., I.B.S.), Los Angeles, California 90095 – sequence: 4 givenname: Robert surname: Elashoff fullname: Elashoff, Robert organization: 1David Geffen School of Medicine at University of California, Los Angeles (K.W.-P., H.W., R.E., B.G., I.B.S.), Los Angeles, California 90095 – sequence: 5 givenname: Barbara surname: Gales fullname: Gales, Barbara organization: 1David Geffen School of Medicine at University of California, Los Angeles (K.W.-P., H.W., R.E., B.G., I.B.S.), Los Angeles, California 90095 – sequence: 6 givenname: Mara J. surname: Horwitz fullname: Horwitz, Mara J. organization: 3The University of Pittsburgh School of Medicine (M.J.H., A.F.S.), Pittsburgh, Pennsylvania 15213 – sequence: 7 givenname: Andrew F. surname: Stewart fullname: Stewart, Andrew F. organization: 3The University of Pittsburgh School of Medicine (M.J.H., A.F.S.), Pittsburgh, Pennsylvania 15213 – sequence: 8 givenname: Harald surname: Jüppner fullname: Jüppner, Harald organization: 4Massachusetts General Hospital and Harvard Medical School (H.J.), Boston, Massachusetts 02114 – sequence: 9 givenname: Isidro B. surname: Salusky fullname: Salusky, Isidro B. organization: 1David Geffen School of Medicine at University of California, Los Angeles (K.W.-P., H.W., R.E., B.G., I.B.S.), Los Angeles, California 90095 |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22884028$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20382692$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kl1rUzEYxw8ycd30zmsJiKwFz8zLecnxQqh12uHAMqt4F9Kc57SpadIl52z0K_kpTW3ndLBACCG__P_P21FyYJ2FJHlO8CmhBL9ZqlOKcZWSClePkh6psjwtSVUeJD2MKUmrkv44TI5CWGJMsixnT5JDihmnRUV7ya_pAtBIGgUrrdAlhLWzAVDr0MjZVtvOdQFNpJftYuOdrtHY-VUMAPUn0_GgT1KWDdC5bbqgnUXaojNbp19bOQf0WdcWNuiDDiCj5HfpNQQ0VMr5Wtv51uP9Vmnaeeuuwb9FQzRxLURbadClM4Aa51H06ZcpzwZPk8eNNAGe7c_j5NvHs-lonF58-XQ-Gl6kKs8KkvIZyfNG5rNK5Y3ihOR1xhSvWSELroDSnPAyV5RVwJnkUs5mDa2gVIpjlpUNO07e7XTX3WwFtYoBeWnE2uuV9BvhpBb_v1i9EHN3LWiFKS5YFDjZC3h31UFoxUoHBcZIC7GcomSMFCUnZSRf3iOXLlYjZiciEpuFSUEi9eLfgP5GctvFCLzaAzIoaRovrdLhjqOcZ5jyyNEdp7wLwUMjlG5lGzsX89BGECy2IyWWSmxHSmxHKn56fe_Tre4DeLbDb5xpwYefprsBLxYgTbsQOK4s5p5STDAu4i2Nm5G7mrlu_ZDBnxFnvwEeSuZ9 |
| CODEN | JCEMAZ |
| CitedBy_id | crossref_primary_10_1007_s00223_010_9414_8 crossref_primary_10_2215_CJN_00550112 crossref_primary_10_3390_metabo12050401 crossref_primary_10_1007_s00467_010_1614_y crossref_primary_10_1186_1471_2369_13_76 crossref_primary_10_1111_nep_14081 crossref_primary_10_1210_clinem_dgac522 crossref_primary_10_4158_EP10324_RA crossref_primary_10_2215_CJN_02740311 crossref_primary_10_1007_s00467_019_04399_0 crossref_primary_10_1016_j_clinbiochem_2012_04_025 crossref_primary_10_1146_annurev_nutr_071816_064620 crossref_primary_10_1016_j_kint_2016_06_041 crossref_primary_10_1177_0300985815586222 crossref_primary_10_1038_ki_2012_176 crossref_primary_10_1016_j_ekir_2024_01_002 crossref_primary_10_1016_j_nefro_2020_12_019 crossref_primary_10_1038_kisup_2011_28 crossref_primary_10_1016_j_nefroe_2021_11_014 crossref_primary_10_1053_j_ajkd_2011_07_027 crossref_primary_10_1097_MNH_0000000000000992 crossref_primary_10_1093_ckj_sfz034 crossref_primary_10_2215_CJN_05940611 crossref_primary_10_2215_CJN_03270314 crossref_primary_10_1016_j_bone_2012_10_008 crossref_primary_10_1038_ki_2015_231 crossref_primary_10_1053_j_jrn_2018_05_006 crossref_primary_10_11005_jbm_24_789 crossref_primary_10_1371_journal_pone_0176411 crossref_primary_10_1016_j_bone_2019_115186 crossref_primary_10_1016_j_semnephrol_2014_09_008 crossref_primary_10_3389_fphar_2021_785375 crossref_primary_10_1007_s00467_012_2324_4 crossref_primary_10_1093_ndt_gfs259 crossref_primary_10_1016_j_nephro_2017_01_002 crossref_primary_10_2215_CJN_06240611 crossref_primary_10_1155_2018_9619253 crossref_primary_10_2215_CJN_0000000000000368 crossref_primary_10_1038_kisup_2013_96 crossref_primary_10_1016_j_tem_2024_02_005 crossref_primary_10_1210_en_2016_1451 crossref_primary_10_1155_2014_381082 crossref_primary_10_1210_clinem_dgac696 crossref_primary_10_1038_ki_2013_150 crossref_primary_10_1210_clinem_dgac698 crossref_primary_10_1080_00365513_2023_2196640 crossref_primary_10_1007_s11255_019_02290_3 crossref_primary_10_1097_TP_0000000000000823 crossref_primary_10_1007_s40620_017_0408_8 crossref_primary_10_1016_j_semnephrol_2014_02_007 crossref_primary_10_3390_nu15194127 |
| Cites_doi | 10.1007/s10157-006-0455-2 10.1359/JBMR.050602 10.1210/jc.2008-0326 10.1038/ki.1994.342 10.1002/jbmr.5650020617 10.1007/s00467-009-1143-8 10.1111/j.1523-1755.2005.00493.x 10.1196/annals.1402.021 10.1046/j.1523-1755.2003.00328.x 10.1210/en.2002-221026 10.1002/jbmr.5650100917 10.1038/sj.ki.5000020 10.1093/oxfordjournals.ndt.a027089 10.1016/S0085-2538(15)47156-X 10.1016/j.jsbmb.2006.12.054 10.1046/j.1523-1755.2001.00949.x 10.1016/j.matbio.2004.09.007 10.1152/ajprenal.00353.2007 10.1530/eje.1.02053 10.1111/j.1523-1755.2005.00517.x 10.1007/s00198-003-1482-4 10.1046/j.1523-1755.2003.00915.x 10.2353/ajpath.2006.060329 10.1093/ndt/gfh876 10.1016/j.bone.2005.03.002 10.1159/000086347 10.1038/ng1868 10.1210/jcem.84.11.6236 10.1172/JCI200419081 10.1111/j.1523-1755.2005.00184.x 10.1210/jc.2006-0021 10.1677/JOE-07-0267 10.1074/jbc.M306019200 10.1210/endo.143.1.8575 10.1046/j.1523-1755.1998.00045.x 10.1046/j.1523-1755.1998.00866.x 10.1046/j.1523-1755.1998.00724.x 10.7326/0003-4819-78-3-357 10.1359/JBMR.0301264 10.1111/j.1523-1755.2005.00178.x 10.1210/jc.2008-0220 10.1210/endo.142.4.8093 10.1210/jc.2002-020773 10.1210/endo-125-3-1617 10.1038/ki.1995.248 10.1172/JCI18399 |
| ContentType | Journal Article |
| Copyright | Copyright © 2010 by The Endocrine Society 2010 Copyright © 2010 by The Endocrine Society 2015 INIST-CNRS Copyright © 2010 by The Endocrine Society 2010 |
| Copyright_xml | – notice: Copyright © 2010 by The Endocrine Society 2010 – notice: Copyright © 2010 by The Endocrine Society – notice: 2015 INIST-CNRS – notice: Copyright © 2010 by The Endocrine Society 2010 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QP 7T5 7TM H94 K9. 7X8 5PM |
| DOI | 10.1210/jc.2009-1909 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Immunology Abstracts Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Calcium & Calcified Tissue Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1945-7197 |
| EndPage | 2780 |
| ExternalDocumentID | PMC2902063 20382692 22884028 10_1210_jc_2009_1909 00004678-201006000-00031 10.1210/jc.2009-1909 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: R01 DK051081 – fundername: NIDDK NIH HHS grantid: R01 DK073039 – fundername: NIDDK NIH HHS grantid: DK-51081 – fundername: NIDDK NIH HHS grantid: R01 DK067563 – fundername: NIDDK NIH HHS grantid: R01 DK035423 – fundername: NIDDK NIH HHS grantid: DK-073039 – fundername: NCRR NIH HHS grantid: RR-00865 – fundername: NCRR NIH HHS grantid: M01 RR000865 – fundername: NIDDK NIH HHS grantid: DK-67563 – fundername: NIDDK NIH HHS grantid: DK-35423 |
| GroupedDBID | --- -~X .55 .XZ 08P 0R~ 18M 1TH 29K 2WC 34G 354 39C 4.4 48X 53G 5GY 5RS 5YH 8F7 AABZA AACZT AAIMJ AAPQZ AAPXW AARHZ AAUAY AAVAP AAWTL ABBLC ABDFA ABEJV ABGNP ABJNI ABLJU ABMNT ABNHQ ABOCM ABPMR ABPPZ ABPQP ABPTD ABQNK ABVGC ABWST ABXVV ACGFO ACGFS ACPRK ACUTJ ACYHN ADBBV ADGKP ADGZP ADHKW ADQBN ADRTK ADVEK AELWJ AEMDU AENEX AENZO AERZD AETBJ AEWNT AFCHL AFFNX AFFZL AFGWE AFOFC AFRAH AFXAL AGINJ AGKRT AGQXC AGUTN AHMBA AHMMS AJEEA ALMA_UNASSIGNED_HOLDINGS APIBT ARIXL ASPBG ATGXG AVWKF AZFZN BAWUL BAYMD BCRHZ BEYMZ BSWAC BTRTY C45 CDBKE CS3 D-I DAKXR DIK E3Z EBS EJD EMOBN ENERS F5P FECEO FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 HZ~ H~9 KBUDW KOP KQ8 KSI KSN L7B M5~ MHKGH MJL N4W N9A NLBLG NOMLY NOYVH NVLIB O9- OAUYM OBH OCB ODMLO OFXIZ OGEVE OHH OJZSN OK1 OPAEJ OVD OVIDX P2P P6G REU ROX ROZ TEORI TJX TLC TR2 TWZ VVN W8F WOQ X7M YBU YFH YHG YOC YSK ZY1 ~02 ~H1 .GJ 3O- 7X7 88E 8FI 8FJ AAJQQ AAKAS AAPGJ AAQQT AAUQX AAWDT AAYJJ ABDPE ABUWG ABXZS ACFRR ACVCV ACZBC ADMTO ADNBA ADZCM AEMQT AEOTA AFFQV AFKRA AFYAG AGMDO AGORE AHGBF AI. AJBYB AJDVS ALXQX APJGH AQDSO AQKUS AVNTJ BENPR BPHCQ BVXVI CCPQU EIHJH FEDTE FYUFA HMCUK HVGLF IAO IHR INH ITC J5H M1P MBLQV NU- OBFPC PHGZM PHGZT PQQKQ PROAC PSQYO TMA UKHRP VH1 WHG X52 ZGI ZXP AAYXX CITATION IQODW PJZUB PPXIY CGR CUY CVF ECM EIF NPM 7QP 7T5 7TM H94 K9. 7X8 5PM |
| ID | FETCH-LOGICAL-c5461-8b155fa5b9c5fc8115d43c8d36a68ce2251875c239e83a8aabbf29e7cc80347f3 |
| ISSN | 0021-972X 1945-7197 |
| IngestDate | Thu Aug 21 14:11:27 EDT 2025 Fri Jul 11 08:23:26 EDT 2025 Mon Jun 30 12:40:49 EDT 2025 Thu Apr 03 07:04:55 EDT 2025 Mon Jul 21 09:14:08 EDT 2025 Thu Apr 24 22:59:10 EDT 2025 Tue Jul 01 02:46:17 EDT 2025 Fri May 16 04:03:20 EDT 2025 Fri Feb 07 10:35:23 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Kidney disease Obesity Urinary system disease Antiosteoporotic Nutrition Continuous Peptide hormone Nutrition disorder Metabolic diseases Osteoarticular system Osteoforming Parathyroid hormone Perfusion Renal failure Turnover Bone Endocrinology Nutritional status Teriparatide |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c5461-8b155fa5b9c5fc8115d43c8d36a68ce2251875c239e83a8aabbf29e7cc80347f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Address all correspondence and requests for reprints to: Katherine Wesseling-Perry, Division of Pediatric Nephrology, A2-383 MDCC, 10833 LeConte Boulevard, Los Angeles, California 90095. E-mail: kwesseling@mednet.ucla.edu. |
| PMID | 20382692 |
| PQID | 3164450161 |
| PQPubID | 2046206 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2902063 proquest_miscellaneous_733167817 proquest_journals_3164450161 pubmed_primary_20382692 pascalfrancis_primary_22884028 crossref_citationtrail_10_1210_jc_2009_1909 crossref_primary_10_1210_jc_2009_1909 wolterskluwer_health_00004678-201006000-00031 oup_primary_10_1210_jc_2009-1909 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2010-June |
| PublicationDateYYYYMMDD | 2010-06-01 |
| PublicationDate_xml | – month: 06 year: 2010 text: 2010-June |
| PublicationDecade | 2010 |
| PublicationPlace | Bethesda, MD |
| PublicationPlace_xml | – name: Bethesda, MD – name: United States – name: Washington |
| PublicationTitle | The journal of clinical endocrinology and metabolism |
| PublicationTitleAlternate | J Clin Endocrinol Metab |
| PublicationYear | 2010 |
| Publisher | Oxford University Press Copyright by The Endocrine Society Endocrine Society The Endocrine Society |
| Publisher_xml | – name: Oxford University Press – name: Copyright by The Endocrine Society – name: Endocrine Society – name: The Endocrine Society |
| References | Sanchez (2020071617560794200_R52) 1998; 53 Horwitz (2020071617560794200_R5) 2005; 20 Martin (2020071617560794200_R48) 2005; 68 Fasciotto (2020071617560794200_R38) 1989; 125 Kazama (2020071617560794200_R43) 2005; 67 Monier-Faugere (2020071617560794200_R50) 2001; 60 Shimada (2020071617560794200_R26) 2004; 19 Langub (2020071617560794200_R37) 2003; 144 John (2020071617560794200_R47) 1999; 84 Kurz (2020071617560794200_R30) 1994; 46 Wesseling-Perry (2020071617560794200_R49) 2009; 24 Lorenz-Depiereux (2020071617560794200_R3) 2006; 38 D'Amour (2020071617560794200_R19) 2005; 68 Kuizon (2020071617560794200_R11) 1998; 53 (2020071617560794200_R12) 2003; 42 Larsson (2020071617560794200_R8) 2003; 64 Riminucci (2020071617560794200_R39) 2003; 112 Sherrard (2020071617560794200_R7) 1986; 6 Nguyen-Yamamoto (2020071617560794200_R35) 2001; 142 Brown (2020071617560794200_R40) 2009; 94 Divieti (2020071617560794200_R14) 2002; 143 Horwitz (2020071617560794200_R17) 2003; 88 Shimada (2020071617560794200_R27) 2004; 113 Yu (2020071617560794200_R42) 2005; 36 Krajisnik (2020071617560794200_R15) 2007; 195 Salusky (2020071617560794200_R20) 2003; 63 Horst (2020071617560794200_R18) 1990; Int Slatopolsky (2020071617560794200_R36) 2000; 58 Sitara (2020071617560794200_R24) 2007; 1116 Kobayashi (2020071617560794200_R2) 2006; 154 Parfitt (2020071617560794200_R22) 1987; 2 Thumfart (2020071617560794200_R25) 2008; 295 Ureña (2020071617560794200_R6) 1995; 47 Nakanishi (2020071617560794200_R44) 2005; 67 Parisien (2020071617560794200_R9) 1995; 10 Sitara (2020071617560794200_R29) 2004; 23 Ureña (2020071617560794200_R31) 1996; 11 Antoniucci (2020071617560794200_R45) 2006; 91 Iwasaki-Ishizuka (2020071617560794200_R32) 2005; 20 Kuwahara (2020071617560794200_R33) 2007; 11 Wesseling-Perry (2020071617560794200_R21) 2009; 94 Mawad (2020071617560794200_R51) 1999; 52 Sneddon (2020071617560794200_R34) 2003; 278 Nishi (2020071617560794200_R1) 2005; 101 Bilezikian (2020071617560794200_R4) 2003; 14 Ben-Dov (2020071617560794200_R16) 2007; 117 Salusky (2020071617560794200_R23) 1998; 54 Barthel (2020071617560794200_R41) 2007; 103 Nagano (2020071617560794200_R46) 2006; 69 Sitara (2020071617560794200_R28) 2006; 169 Massry (2020071617560794200_R13) 1973; 78 Quarles (2020071617560794200_R10) 1992; 75 7502712 - J Bone Miner Res. 1995 Sep;10(9):1393-9 17911404 - J Endocrinol. 2007 Oct;195(1):125-31 17033625 - Nat Genet. 2006 Nov;38(11):1248-50 14633152 - Kidney Int. 2003 Dec;64(6):2272-9 11250917 - Endocrinology. 2001 Apr;142(4):1386-92 17148678 - Am J Pathol. 2006 Dec;169(6):2161-70 12639892 - Endocrinology. 2003 Apr;144(4):1135-8 7643551 - Kidney Int. 1995 Jun;47(6):1797-805 15985520 - Nephrol Dial Transplant. 2005 Sep;20(9):1904-11 12920119 - J Biol Chem. 2003 Oct 31;278(44):43787-96 15579309 - Matrix Biol. 2004 Nov;23(7):421-32 15698459 - Kidney Int. 2005 Mar;67(3):1171-8 14966565 - J Clin Invest. 2004 Feb;113(4):561-8 14520607 - Am J Kidney Dis. 2003 Oct;42(4 Suppl 3):S1-201 18701629 - Am J Physiol Renal Physiol. 2008 Oct;295(4):F1126-33 11576360 - Kidney Int. 2001 Oct;60(4):1460-8 2759035 - Endocrinology. 1989 Sep;125(3):1617-22 17646263 - Ann N Y Acad Sci. 2007 Nov;1116:485-93 1619003 - J Clin Endocrinol Metab. 1992 Jul;75(1):145-50 16105030 - Kidney Int. 2005 Sep;68(3):998-1007 2170736 - Kidney Int Suppl. 1990 Sep;29:S28-35 9453020 - Kidney Int. 1998 Jan;53(1):205-11 18854401 - J Clin Endocrinol Metab. 2009 Jan;94(1):17-20 19301038 - Pediatr Nephrol. 2009 Jul;24(7):1355-61 16735491 - J Clin Endocrinol Metab. 2006 Aug;91(8):3144-9 16395276 - Kidney Int. 2006 Feb;69(3):531-7 17384996 - Clin Exp Nephrol. 2007 Mar;11(1):34-40 7996807 - Kidney Int. 1994 Sep;46(3):855-61 12679445 - J Clin Endocrinol Metab. 2003 Apr;88(4):1603-9 12675856 - Kidney Int. 2003 May;63(5):1801-8 9573553 - Kidney Int. 1998 May;53(5):1358-64 11751606 - Endocrinology. 2002 Jan;143(1):171-6 16105056 - Kidney Int. 2005 Sep;68(3):1236-43 19050056 - J Clin Endocrinol Metab. 2009 Feb;94(2):511-7 17293108 - J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):381-8 12952917 - J Clin Invest. 2003 Sep;112(5):683-92 8918715 - Nephrol Dial Transplant. 1996 Oct;11(10):2008-16 4571863 - Ann Intern Med. 1973 Mar;78(3):357-64 10499311 - Clin Nephrol. 1999 Sep;52(3):160-6 3299577 - Semin Nephrol. 1986 Mar;6(1):56-67 3455637 - J Bone Miner Res. 1987 Dec;2(6):595-610 15869926 - Bone. 2005 Jun;36(6):971-7 15956805 - Nephron Clin Pract. 2005;101(2):c94-9 16160737 - J Bone Miner Res. 2005 Oct;20(10):1792-803 16381997 - Eur J Endocrinol. 2006 Jan;154(1):93-9 10566687 - J Clin Endocrinol Metab. 1999 Nov;84(11):4287-90 14504715 - Osteoporos Int. 2003 Sep;14 Suppl 5:S113-5; discussion S115-7 10916099 - Kidney Int. 2000 Aug;58(2):753-61 15698453 - Kidney Int. 2005 Mar;67(3):1120-5 9734615 - Kidney Int. 1998 Sep;54(3):907-14 15040831 - J Bone Miner Res. 2004 Mar;19(3):429-35 17992255 - J Clin Invest. 2007 Dec;117(12):4003-8 |
| References_xml | – volume: 11 start-page: 34 year: 2007 ident: 2020071617560794200_R33 article-title: Expression of bone type 1 PTH receptor in rats with chronic renal failure publication-title: Clin Exp Nephrol doi: 10.1007/s10157-006-0455-2 – volume: 20 start-page: 1792 year: 2005 ident: 2020071617560794200_R5 article-title: Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D publication-title: J Bone Miner Res doi: 10.1359/JBMR.050602 – volume: 6 start-page: 56 year: 1986 ident: 2020071617560794200_R7 article-title: Renal osteodystrophy publication-title: Semin Nephrol – volume: 94 start-page: 511 year: 2009 ident: 2020071617560794200_R21 article-title: Relationship between plasma FGF-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2008-0326 – volume: 46 start-page: 855 year: 1994 ident: 2020071617560794200_R30 article-title: Evidence for abnormal calcium homeostasis in patients with adynamic bone disease publication-title: Kidney Int doi: 10.1038/ki.1994.342 – volume: 2 start-page: 595 year: 1987 ident: 2020071617560794200_R22 article-title: Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee publication-title: J Bone Miner Res doi: 10.1002/jbmr.5650020617 – volume: 24 start-page: 1355 year: 2009 ident: 2020071617560794200_R49 article-title: Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols publication-title: Pediatr Nephrol doi: 10.1007/s00467-009-1143-8 – volume: 68 start-page: 998 year: 2005 ident: 2020071617560794200_R19 article-title: Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism publication-title: Kidney Int doi: 10.1111/j.1523-1755.2005.00493.x – volume: 1116 start-page: 485 year: 2007 ident: 2020071617560794200_R24 article-title: Correlation among hyperphosphatemia, type II sodium phosphate transporter activity, and vitamin D metabolism in Fgf-23 null mice publication-title: Ann NY Acad Sci doi: 10.1196/annals.1402.021 – volume: 64 start-page: 2272 year: 2003 ident: 2020071617560794200_R8 article-title: Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers publication-title: Kidney Int doi: 10.1046/j.1523-1755.2003.00328.x – volume: 144 start-page: 1135 year: 2003 ident: 2020071617560794200_R37 article-title: Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure publication-title: Endocrinology doi: 10.1210/en.2002-221026 – volume: 10 start-page: 1393 year: 1995 ident: 2020071617560794200_R9 article-title: Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women publication-title: J Bone Miner Res doi: 10.1002/jbmr.5650100917 – volume: 69 start-page: 531 year: 2006 ident: 2020071617560794200_R46 article-title: Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats publication-title: Kidney Int doi: 10.1038/sj.ki.5000020 – volume: 11 start-page: 2008 year: 1996 ident: 2020071617560794200_R31 article-title: PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uraemic rats publication-title: Nephrol Dial Transplant doi: 10.1093/oxfordjournals.ndt.a027089 – volume: 58 start-page: 753 year: 2000 ident: 2020071617560794200_R36 article-title: A novel mechanism for skeletal resistance in uremia publication-title: Kidney Int doi: 10.1016/S0085-2538(15)47156-X – volume: 103 start-page: 381 year: 2007 ident: 2020071617560794200_R41 article-title: 1,25-Dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism publication-title: J Steroid Biochem Mol Biol doi: 10.1016/j.jsbmb.2006.12.054 – volume: 60 start-page: 1460 year: 2001 ident: 2020071617560794200_R50 article-title: Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients publication-title: Kidney Int doi: 10.1046/j.1523-1755.2001.00949.x – volume: 23 start-page: 421 year: 2004 ident: 2020071617560794200_R29 article-title: Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice publication-title: Matrix Biol doi: 10.1016/j.matbio.2004.09.007 – volume: 295 start-page: F1126 year: 2008 ident: 2020071617560794200_R25 article-title: Magnesium stimulates renal phosphate reabsorption publication-title: Am J Physiol Renal Physiol doi: 10.1152/ajprenal.00353.2007 – volume: 154 start-page: 93 year: 2006 ident: 2020071617560794200_R2 article-title: Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism publication-title: Eur J Endocrinol doi: 10.1530/eje.1.02053 – volume: 68 start-page: 1236 year: 2005 ident: 2020071617560794200_R48 article-title: First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl publication-title: Kidney Int doi: 10.1111/j.1523-1755.2005.00517.x – volume: 14 start-page: S113 issue: Suppl 5 year: 2003 ident: 2020071617560794200_R4 article-title: Bone strength in primary hyperparathyroidism publication-title: Osteoporos Int doi: 10.1007/s00198-003-1482-4 – volume: 63 start-page: 1801 year: 2003 ident: 2020071617560794200_R20 article-title: Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis publication-title: Kidney Int doi: 10.1046/j.1523-1755.2003.00915.x – volume: 42 start-page: S1 issue: Suppl 3 year: 2003 ident: 2020071617560794200_R12 article-title: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease publication-title: Am J Kidney Dis – volume: 52 start-page: 160 year: 1999 ident: 2020071617560794200_R51 article-title: Calcific uremic arteriolopathy in association with low turnover uremic bone disease publication-title: Clin Nephrol – volume: 169 start-page: 2161 year: 2006 ident: 2020071617560794200_R28 article-title: Genetic ablation of vitamin d activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals publication-title: Am J Pathol doi: 10.2353/ajpath.2006.060329 – volume: 20 start-page: 1904 year: 2005 ident: 2020071617560794200_R32 article-title: Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfh876 – volume: 36 start-page: 971 year: 2005 ident: 2020071617560794200_R42 article-title: Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations publication-title: Bone doi: 10.1016/j.bone.2005.03.002 – volume: 101 start-page: c94 year: 2005 ident: 2020071617560794200_R1 article-title: Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism publication-title: Nephron Clin Pract doi: 10.1159/000086347 – volume: 38 start-page: 1248 year: 2006 ident: 2020071617560794200_R3 article-title: DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis publication-title: Nat Genet doi: 10.1038/ng1868 – volume: 84 start-page: 4287 year: 1999 ident: 2020071617560794200_R47 article-title: A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem.84.11.6236 – volume: 113 start-page: 561 year: 2004 ident: 2020071617560794200_R27 article-title: Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism publication-title: J Clin Invest doi: 10.1172/JCI200419081 – volume: 67 start-page: 1171 year: 2005 ident: 2020071617560794200_R44 article-title: Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients publication-title: Kidney Int doi: 10.1111/j.1523-1755.2005.00184.x – volume: 91 start-page: 3144 year: 2006 ident: 2020071617560794200_R45 article-title: Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2006-0021 – volume: 195 start-page: 125 year: 2007 ident: 2020071617560794200_R15 article-title: Fibroblast growth factor-23 regulates parathyroid hormone and 1α-hydroxylase expression in cultured bovine parathyroid cells publication-title: J Endocrinol doi: 10.1677/JOE-07-0267 – volume: 278 start-page: 43787 year: 2003 ident: 2020071617560794200_R34 article-title: Activation-independent parathyroid hormone receptor internalization is regulated by NHERF1 (EBP50) publication-title: J Biol Chem doi: 10.1074/jbc.M306019200 – volume: 143 start-page: 171 year: 2002 ident: 2020071617560794200_R14 article-title: Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor publication-title: Endocrinology doi: 10.1210/endo.143.1.8575 – volume: 54 start-page: 907 year: 1998 ident: 2020071617560794200_R23 article-title: Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration publication-title: Kidney Int doi: 10.1046/j.1523-1755.1998.00045.x – volume: 53 start-page: 1358 year: 1998 ident: 2020071617560794200_R52 article-title: Bone disease in children and adolescents undergoing successful renal transplantation publication-title: Kidney Int doi: 10.1046/j.1523-1755.1998.00866.x – volume: 53 start-page: 205 year: 1998 ident: 2020071617560794200_R11 article-title: Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD publication-title: Kidney Int doi: 10.1046/j.1523-1755.1998.00724.x – volume: 78 start-page: 357 year: 1973 ident: 2020071617560794200_R13 article-title: Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects publication-title: Ann Intern Med doi: 10.7326/0003-4819-78-3-357 – volume: 19 start-page: 429 year: 2004 ident: 2020071617560794200_R26 article-title: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis publication-title: J Bone Miner Res doi: 10.1359/JBMR.0301264 – volume: 67 start-page: 1120 year: 2005 ident: 2020071617560794200_R43 article-title: Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients publication-title: Kidney Int doi: 10.1111/j.1523-1755.2005.00178.x – volume: 117 start-page: 4003 year: 2007 ident: 2020071617560794200_R16 article-title: The parathyroid is a target organ for FGF23 in rats publication-title: J Clin Invest – volume: Int start-page: S28 issue: Suppl 29 year: 1990 ident: 2020071617560794200_R18 article-title: Improved methodology for the analysis of plasma vitamin D metabolites publication-title: Kidney – volume: 94 start-page: 17 year: 2009 ident: 2020071617560794200_R40 article-title: Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen’s metaphyseal chondrodysplasia publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2008-0220 – volume: 142 start-page: 1386 year: 2001 ident: 2020071617560794200_R35 article-title: Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor publication-title: Endocrinology doi: 10.1210/endo.142.4.8093 – volume: 88 start-page: 1603 year: 2003 ident: 2020071617560794200_R17 article-title: Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2002-020773 – volume: 125 start-page: 1617 year: 1989 ident: 2020071617560794200_R38 article-title: Pancreastatin, a presumed product of chromogranin-A (secretory protein-I) processing, inhibits secretion from porcine parathyroid cells in culture publication-title: Endocrinology doi: 10.1210/endo-125-3-1617 – volume: 47 start-page: 1797 year: 1995 ident: 2020071617560794200_R6 article-title: Parathyroidectomy does not prevent the renal PTH/PTHrP receptor down-regulation in uremic rats publication-title: Kidney Int doi: 10.1038/ki.1995.248 – volume: 112 start-page: 683 year: 2003 ident: 2020071617560794200_R39 article-title: FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting publication-title: J Clin Invest doi: 10.1172/JCI18399 – volume: 75 start-page: 145 year: 1992 ident: 2020071617560794200_R10 article-title: Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia publication-title: J Clin Endocrinol Metab – reference: 17293108 - J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):381-8 – reference: 9734615 - Kidney Int. 1998 Sep;54(3):907-14 – reference: 11751606 - Endocrinology. 2002 Jan;143(1):171-6 – reference: 10499311 - Clin Nephrol. 1999 Sep;52(3):160-6 – reference: 17992255 - J Clin Invest. 2007 Dec;117(12):4003-8 – reference: 1619003 - J Clin Endocrinol Metab. 1992 Jul;75(1):145-50 – reference: 14633152 - Kidney Int. 2003 Dec;64(6):2272-9 – reference: 16105056 - Kidney Int. 2005 Sep;68(3):1236-43 – reference: 16395276 - Kidney Int. 2006 Feb;69(3):531-7 – reference: 12920119 - J Biol Chem. 2003 Oct 31;278(44):43787-96 – reference: 17033625 - Nat Genet. 2006 Nov;38(11):1248-50 – reference: 8918715 - Nephrol Dial Transplant. 1996 Oct;11(10):2008-16 – reference: 7502712 - J Bone Miner Res. 1995 Sep;10(9):1393-9 – reference: 3455637 - J Bone Miner Res. 1987 Dec;2(6):595-610 – reference: 15040831 - J Bone Miner Res. 2004 Mar;19(3):429-35 – reference: 17148678 - Am J Pathol. 2006 Dec;169(6):2161-70 – reference: 14504715 - Osteoporos Int. 2003 Sep;14 Suppl 5:S113-5; discussion S115-7 – reference: 18854401 - J Clin Endocrinol Metab. 2009 Jan;94(1):17-20 – reference: 16381997 - Eur J Endocrinol. 2006 Jan;154(1):93-9 – reference: 17384996 - Clin Exp Nephrol. 2007 Mar;11(1):34-40 – reference: 15579309 - Matrix Biol. 2004 Nov;23(7):421-32 – reference: 16160737 - J Bone Miner Res. 2005 Oct;20(10):1792-803 – reference: 12952917 - J Clin Invest. 2003 Sep;112(5):683-92 – reference: 7643551 - Kidney Int. 1995 Jun;47(6):1797-805 – reference: 9573553 - Kidney Int. 1998 May;53(5):1358-64 – reference: 3299577 - Semin Nephrol. 1986 Mar;6(1):56-67 – reference: 2759035 - Endocrinology. 1989 Sep;125(3):1617-22 – reference: 16735491 - J Clin Endocrinol Metab. 2006 Aug;91(8):3144-9 – reference: 11250917 - Endocrinology. 2001 Apr;142(4):1386-92 – reference: 14520607 - Am J Kidney Dis. 2003 Oct;42(4 Suppl 3):S1-201 – reference: 7996807 - Kidney Int. 1994 Sep;46(3):855-61 – reference: 4571863 - Ann Intern Med. 1973 Mar;78(3):357-64 – reference: 15698459 - Kidney Int. 2005 Mar;67(3):1171-8 – reference: 15698453 - Kidney Int. 2005 Mar;67(3):1120-5 – reference: 15869926 - Bone. 2005 Jun;36(6):971-7 – reference: 2170736 - Kidney Int Suppl. 1990 Sep;29:S28-35 – reference: 12675856 - Kidney Int. 2003 May;63(5):1801-8 – reference: 9453020 - Kidney Int. 1998 Jan;53(1):205-11 – reference: 12639892 - Endocrinology. 2003 Apr;144(4):1135-8 – reference: 15956805 - Nephron Clin Pract. 2005;101(2):c94-9 – reference: 10566687 - J Clin Endocrinol Metab. 1999 Nov;84(11):4287-90 – reference: 17646263 - Ann N Y Acad Sci. 2007 Nov;1116:485-93 – reference: 18701629 - Am J Physiol Renal Physiol. 2008 Oct;295(4):F1126-33 – reference: 16105030 - Kidney Int. 2005 Sep;68(3):998-1007 – reference: 15985520 - Nephrol Dial Transplant. 2005 Sep;20(9):1904-11 – reference: 12679445 - J Clin Endocrinol Metab. 2003 Apr;88(4):1603-9 – reference: 10916099 - Kidney Int. 2000 Aug;58(2):753-61 – reference: 17911404 - J Endocrinol. 2007 Oct;195(1):125-31 – reference: 11576360 - Kidney Int. 2001 Oct;60(4):1460-8 – reference: 14966565 - J Clin Invest. 2004 Feb;113(4):561-8 – reference: 19301038 - Pediatr Nephrol. 2009 Jul;24(7):1355-61 – reference: 19050056 - J Clin Endocrinol Metab. 2009 Feb;94(2):511-7 |
| SSID | ssj0014453 |
| Score | 2.2490811 |
| Snippet | Context: Factors contributing to PTH resistance in dialysis patients remain elusive.
Objectives: The study assessed the skeletal and biochemical response to 46... CONTEXT:Factors contributing to PTH resistance in dialysis patients remain elusive. OBJECTIVES:The study assessed the skeletal and biochemical response to 46 h... Factors contributing to PTH resistance in dialysis patients remain elusive. The study assessed the skeletal and biochemical response to 46 h of PTH(1-34)... Context: Factors contributing to PTH resistance in dialysis patients remain elusive. Objectives: The study assessed the skeletal and biochemical response to 46... Factors contributing to PTH resistance in dialysis patients remain elusive.CONTEXTFactors contributing to PTH resistance in dialysis patients remain... Context: Factors contributing to PTH resistance in dialysis patients remain elusive. Objectives: The study assessed the skeletal and biochemical response to 46... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref wolterskluwer oup |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2772 |
| SubjectTerms | Adolescent Biological and medical sciences Biopsy Bone and Bones - drug effects Bone and Bones - metabolism Bone and Bones - pathology Bone Development - drug effects Bone turnover Calcification, Physiologic - drug effects Calcium - blood Calcium - urine Dialysis Disease resistance End-stage renal disease Endocrinopathies Feeding. Feeding behavior Female Fibroblast growth factor 23 Fibroblast Growth Factors - blood Fundamental and applied biological sciences. Psychology Hemodialysis Humans Kidney diseases Kidney Failure, Chronic - drug therapy Kidney Failure, Chronic - pathology Male Medical sciences Original Parathyroid hormone Parathyroid Hormone - physiology Parathyroid Hormone - therapeutic use Peptide Fragments - physiology Phosphorus Phosphorus - blood Renal Dialysis Skeleton Vertebrates: anatomy and physiology, studies on body, several organs or systems Vertebrates: endocrinology Vitamin D Young Adult |
| Title | The Calcemic Response to Continuous Parathyroid Hormone (PTH)(1-34) Infusion in End-Stage Kidney Disease Varies According to Bone Turnover: A Potential Role for PTH(7-84) |
| URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004678-201006000-00031 https://www.ncbi.nlm.nih.gov/pubmed/20382692 https://www.proquest.com/docview/3164450161 https://www.proquest.com/docview/733167817 https://pubmed.ncbi.nlm.nih.gov/PMC2902063 |
| Volume | 95 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1taxQxEA61gghFfPe0lnyw0Hqk3L4nfqtt5WqpHHKVfluy2ay92u6We0H0J_krnUmyL0db0H5Zjtuw2WXmmcwkz8wQ8k7GYSb4QLKsCCMW8kHApPJzpiSPdC5ELiQmOB9_iYcn4efT6HTl3vsOa2kxz3bU7xvzSu4iVfgP5IpZsv8h2eah8Af8BvnCFSQM13-W8Z68UIbg_tWyXU0rDKw5NSkXSG8dYW3vs1_TapL3h-CgVtarHI2Hm77AKk0sCHFr4LAsFjNHfDwocwZe6HfdP5rkJViNfXuM0_9mImvTYmJqsmFgro_4xDG8rSGDmkT3UTVHEhLW7UfyIjIZzXxgaXhY7z2ct9_QKV_RZGrqMq_AopVtjahLPQeNvahrHprjpJnNp2cjPbV8gKM6o7E1rXgaYPf_d2wthfYQwRq6oWbn9QpuaCxydlbZapWWeN7dGsFT_bi7NYIfcOBeVtcs2O5igOyUxHRzh6XQ2n8BGpt4ljJcLxC2C6gDwpK1T2zbIec5-IltSnVtVYKwGlclUzFTMHDBRHcYSObq0mioPwgg2hN-uzY3jMnR8Z4vwLWPg3vkPs6L3Tr2D4-aE7MwdBVX3Ue5JA_M0OpOjMWv3SxLnpjN7ly7kjMQcWF7utwUdF3nDq_9rJDXMfth0jo6ztn4MXnkoiq6ayHyhKzo8il5cOx4I8_IHxASrZFCa6TQeUVbpNAOUqhDCt0Cvd3eQoxs0xohdFLSBiHUIoQ6hFCLENogBOdAhNAaIR_oLm3wQREfFPBBYZ4tRMf2c3Ly6WC8N2SuSwlTURh7jGfgkhcyyoRCPiREWHkYKJ4HsYy50rBeejyJlB8IzQPJpcyywhc6UQoMY5gUwQuyWsJ7vCK00DH4HnmmPC3hTiyF4jovYi1kht3ge6RfSyxVroQ_dpK5SDGUB1Gn5wr7yooURd0jm83oK1u65pZxFIR_2xBmh2wsaUYz2Pc5DyFE6ZH1WlVSZzNmaeBBsBVhTAlTNLdh-cIzSVlqEG2KLWPBX_aSHnlpFat9ttPTHkmWVK4ZgJXxl--UkzNTId9BpUfYknKmNrc8NRsjMCtDozGIXXGNwHt955nekIetAVonq_PpQr-FaGWebRiY_gXnnT0L |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Calcemic+Response+to+Continuous+Parathyroid+Hormone+%28PTH%29%281-34%29+Infusion+in+End-Stage+Kidney+Disease+Varies+According+to+Bone+Turnover%3A+A+Potential+Role+for+PTH%287-84%29&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Wesseling-Perry%2C+Katherine&rft.au=Harkins%2C+G.+Chris&rft.au=Wang%2C+He-jing&rft.au=Elashoff%2C+Robert&rft.date=2010-06-01&rft.pub=The+Endocrine+Society&rft.issn=0021-972X&rft.eissn=1945-7197&rft.volume=95&rft.issue=6&rft.spage=2772&rft.epage=2780&rft_id=info:doi/10.1210%2Fjc.2009-1909&rft_id=info%3Apmid%2F20382692&rft.externalDocID=PMC2902063 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon |